title: [The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic].
abstract: A functional connection between the small intestine and endocrine pancreas was proved in the sixties, after it became possible to determine the exact amount of insulin in plasma. The insulin response after oral doses of glucose is substantially stronger than after intravenous doses of sugar, even when identical glucose plasma levels are attained. This incretin effect is explained by the connection of the entero-insular axis. The intestinal hormones, that are released by the small intestine after meals, circulate measurably in plasma, and strengthen the glucose-induced insulin secretion, are responsible for this effect. In addition to the classical incretin hormone "Gastric inhibitory polypeptide-1" (GIP), "Glucagon-like peptide-1" (GLP-1) is very interesting to investigators today. In a relatively short amount of time, GLP-1 has matured from a physiologically interesting incretin hormone candidate to a potentially therapeutical alternative for the treatment of diabetes mellitus. GLP-1 stimulates glucose-dependent insulin secretion, decreases plasma glucagon levels, delays gastric emptying, and putatively exerts an additional effect on peripheral glucose utilization. On top of that, GLP-1 has effects on the central nervous system thereby impacting on feeding behavior.
authors.affiliation: Klinische Forschergruppe für Gastrointestinale Endokrinologie am Zentrum für Innere Medizin, Philipps Universität Marburg.
authors.forename: B
authors.initials: B
authors.lastname: Göke
authors.forename: H C
authors.initials: HC
authors.lastname: Fehmann
authors.forename: J
authors.initials: J
authors.lastname: Schirra
authors.forename: A
authors.initials: A
authors.lastname: Hareter
authors.forename: R
authors.initials: R
authors.lastname: Göke
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000503:physiopathology / Q000628:therapy; D005768:Gastrointestinal Hormones / Q000502:physiology*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007328:Insulin / Q000097:blood*; D010455:Peptides / Q000502:physiology* / Q000627:therapeutic use; D019518:Postprandial Period / Q000502:physiology
chemical_list: D001786:Blood Glucose; D005768:Gastrointestinal Hormones; D007328:Insulin; D010455:Peptides; D052216:Glucagon-Like Peptide 1